Treatment of liver cancer of middle and advanced stages using ultrasound-guided percutaneous ethanol injection combined with radiofrequency ablation: A clinical analysis

Abstract

Liver cancer is a malignancy of the digestive system and has a high morbidity and mortality rate. Local intervention has become a viable option in identifying liver treatment. The aim of the present study was to analyze the clinical effects of treating liver cancer in middle and advanced stages using ultrasound-guided percutaneous ethanol injection (PEI) in tumors combined with radiofrequency ablation (RFA). A total of 100 patients with stage III–IV liver cancers were selected to participate in the study. Patients were divided into groups. In group A, treatment was initiated with PEI and after 1–2 weeks RFA was applied while in group B treatment was initiated with RFA and after 1–2 weeks PEI was applied. Patients in group C received PEI and RFA simultaneously. The clinical effects in the 3 groups were compared after 6-month follow ups. The volume of tumor ablation necrosis in group A was significantly greater than that in the groups B and C, while the size was significantly smaller compared to groups B and C after ablation. For group A, the complete ablation rate was significantly higher than that in groups B and C, and the differences were statistically significant (P<0.05). Liver damage indices, including raising levels of glutamic-pyruvic transaminase and total bilirubin, were significantly decreased in group A (P<0.05). The survival rate in group A was also significantly higher than in groups B and C (P<0.05). In conclusion, for patients with liver cancer in middle and advanced stages, the treatment method using PEI followed by RFA was more beneficial in terms of improving the tumor ablation rate, alleviating liver damages and increasing survival rates.

Introduction

Liver cancer is a malignant tumor of the digestive system with the highest morbidity and mortality rate in China. Early symptoms are often not typical and clinical diagnoses usually occur during middle and advanced stages. Consequently, the surgical resection rate is extremely low at 5–20% (1). Local tumor intervention treatment has become a viable option for the treatment of liver cancer. In addition, ultrasound-guided percutaneous ethanol injection (PEI) in tumors and percutaneous radiofrequency ablation (RFA) in early stage and small hepatocellular carcinoma have become increasingly applied. These methods were shown to be effective for obtaining a comparable clinical effect compared to surgical resections (2), and also have other advantages such as negligible trauma, extremely low rates of complications and are readily accepted by doctors and patients. However, in cases of tumor ablation without the background of ‘pseudocapsule’ there is a risk of alcohol diffusion during the injection which may damage the normal liver tissue (3). RFA also has a few advantages including ‘thermal subsidence’ and ‘three-dimensional leakage effect’. Nevertheless, it is not effective in cases of larger tumors and tumors located in particular areas of the body, such as the aorta, diaphragmatic surface, gall bladder and heart (4).

Several studies on the application of PEI in combination with RFA for the treatment of small hepatocellular carcinoma and liver cancer are available (5). However, the application of PEI in combination with RFA to treat liver cancer in middle and advanced stages has yet to be examined.

Patients and methods

Patients

Between March 2013 and March 2015, 100 patients diagnosed with stage III–IV (Union for International Cancer Control stages) liver cancer were selected. The study conformed to interventional treatment testimony. Approval was obtained from the Ethics Committee of Zhengzhou Central Hospital Affiliated to Zhengzhou University and informed consent was provided by patients and their families.

The inclusion criteria for the study were: i) Patients were mentally conscious; ii) all tumors were <8 cm in diameter and the total number of tumors was <6; and iii) it was the first time patients were treated using PEI and RFA. The exclusion criteria for the study were: i) Patients with hepatic metastasis; ii) pregnant patients and those with serious coagulation mechanism disorders as well as those with medical histories of liver cancer resection and chemoradiotherapy and serious cachexia; iii) patients who had <6 months survival expectancy; and iv) patients who were intolerant to surgery and those with interrupted treatments, and missed follow ups.

According to the selective treatment plan, the patients were divided into 3 groups. In group A (n=35), treatment was initiated with PEI and after 1–2 weeks RFA was applied, while in group B (n=33) treatment was initiated with RFA and after 1–2 weeks PEI was applied. Patients in group C received PEI and RFA simultaneously. The clinical effects in the 3 groups were compared after 6 months.

Group A, comprised 20 male and 15 female patients, with an age range of 56–72 years and an average age of 63.4±10.5 years. The mean tumor size was 4.6±1.3 cm (range, 3.0–5.5 cm) and the total number of tumors was 1–4 with an average of 2.7±1.3. There were 16 patients with liver function classification Child-Pugh B and 19 patients with Child-Pugh C, of which 5 cases had tumors in paricular regions and 30 cases had other conditions. In group B, there were 17 male and 16 female patients, with an age range of 55–71 years and an average age of 61.7±12.3 years. The mean tumor size was 4.3±1.4 cm (range, 2.8–5.6 cm) and the total number of tumors was 1–4 with an average of 2.3±1.5. In group B there were 18 patients with liver function classification Child-Pugh B and 15 patients with Child-Pugh C, of which 4 cases had tumors in particular areas and 29 patients had other conditions. Group C, comprised of 19 male and 13 female patients with an age range of 54–75 years and average age of 63.6±15.2 years. The mean tumor size was 4.7±1.2 cm (range, 3.5–6.0 cm) and the total number of tumors was 1–4 with an average of 2.3±1.5. There were 17 patients with liver function classification Child-Pugh B and 15 patients with Child-Pugh C of which 5 cases of tumors were in particular areas and 27 patients had other conditions. The comparisons of baseline information for the 3 groups showed that the differences were not statistically significant (P>0.05).

Treatments

The patient was placed in supine position and PEI was performed under general anesthesia, using percutaneous puncture needling guided by ultrasound (Aloka SSD-1100 Color Doppler Ultrasound; Siemens AG, Munich, Germany). Local anesthesia was performed using lidocaine. A 22G EV needle (Hakko Co., Ltd., Tokyo, Japan) was entered into the tumor by percutaneous liver biopsy, no blood and gail were evident when the syringe was withdrawn. Using a 10 ml syringe, anhydrous alcohol was uniformly injected into the tumor within 30–60 sec. After the alcohol injection, a high echogenic mass was observed under ultrasound that spread from the pinpoint. Injections were stopped when the high echogenic mass fully covered the tumor and surpassed the edge by >0.5 cm. The injection volume was calculated using the formula: V=4/3π (r+0.5)³ where V is total volume, and r is the radius of lesion. After completion of injection, the puncture needle was gradually withdrawn. Drug overflow was avoided as the procedure was observed under ultrasound. After withdrawal of the puncture needle, the puncture point was covered with gauze and pressured was applied on the dressing (Fig. 1).

Figure 1.

The process of percutaneous ethanol injection.

RFA was performed under general anesthesia once the patient was in supine position, using percutaneous puncture needling guided by ultrasound (Aloka SSD-1100 Color Doppler Ultrasound; Siemens AG). Local anesthesia was performed using lidocaine. The cool-tip RF System (Valleylab, Boulder, CO, USA), uni-polar cold circulation system, mating electrode wire and plate electrode were used during the process. Output frequency was adjusted to (1±5%) 460 kHz, the maximum power was 150 W and the needle used was a 14 G trocar. A total of 7–12 fine needle electrodes were set on top of the inner needles, which formed a 5.0 cm spherical heat coagulation after stretching energization. The unit was set to 90 W for RFA actual burning power and the temperature was set at 100°C. After the temperature reached 100°C, it was maintained for 15 min. Following completion of a single RFA, the echo of the ablation area under the observation of ultrasound was higher, the position of the needle electrodes was adjusted according to the tumor size for repeated ablation, in order to cover the whole target tumor in the echo area, and the ablation area surpassed tumor lesions by 0.5–1 cm. Following completion of the treatment, the stretching electrodes were withdrawn, and the needles were withdrawn after burning of closed needles. The adjustments of radiofrequency power started from 60 W each time, and it were gradually elevated until impedance markedly increased and power was automatically reduced. The scope of vaporization of strong echo covering all boundaries of the tumors was used to detrermine when to terminate the treatment. To prevent hemorrhage and implantation metastasis, needles were heated under high temperature each time prior to use (Fig. 2).

Figure 2.

The process of radiofrequency ablation.

Observation indices

The volume of tumor ablation necrosis, volume after ablation and complete ablation rate, quantity of alcohol and radiofrequency energy used and liver function damage indices, including raising levels of glutamic-pyruvic transaminase and total bilirubin were recorded. Differences of survival rates were compared 6 months after follow-ups. To determine tumor volume the formula used was: V(cm³)=4/3 × r1(cm) × r2 (cm) × r3(cm), (r1=longest diameter/2, r2=shortest diameter/2, r3=height/2). The volume of tumor necrosis was calculated by subtracting the volume after ablation from the volume before ablation. A contrast-enhanced ultrasound examination was conducted two weeks after the treatment. Arterial portal and delayed phases of the ablation area with no contrast agent observed was regarded as complete ablation; radiofrequency energy (J)=watt (W) × curative time (sec).

Statistical analysis

SPSS 20.0 software (IBM SPSS, Armonk, NY, USA) was used for statistical analyses. Measurement data were presented by mean ± standard deviation. Analysis of variance was used for comparisons among the groups and enumeration data were presented by %, while the χ² test was used for comparison among groups. P<0.05 was considered to indicate a statistically significant difference.

Results

Comparisons of ablation parameters

The volume of tumor ablation necrosis in group A was significantly larger than that in groups B and C, while the volume was significantly smaller than that in groups B and C after ablation. The complete ablation rate in group A was significantly higher than that in groups B and C, and the differences were statistically significant (P<0.05). The comparisons of quantity of alcohol used and radiofrequency energy in the three groups showed that the differences were not statistically significant (P>0.05) (Table I).

Table I.

Comparisons among different ablation parameters.

Groups	Cases	Volume before ablation (cm3)	Volume after ablation	Volume of necrosis ablation	Complete ablation rate (%)	Usage volume of alcohol, ml	Radiofrequency energy (×103 J)
A	35	15.5±3.3	1.5±0.8	13.8±4.2	30 (85.7)	8.5±1.3	456.7±33.4
B	33	14.7±3.4	6.6±1.2	10.6±3.7	20 (60.6)	8.2±1.5	432.6±45.2
C	32	15.3±3.5	7.2±1.5	10.5±3.8	20 (62.5)	8.3±1.6	423.4±43.3
F (χ2)		0.632	6.926	6.524	6.360	0.423	0.938
P-value		0.425	0.032	0.038	0.042	0.725	0.546

Group A, PEI was administered first and then RFA; group B, RFA was administered first and then PEI; group C, PEI and RFA were administered simultaneously. PEI, percutaneous ethanol injection; RFA, radiofrequency ablation.

Comparisons of liver function damage indices

The comparisons of glutamic-pyruvic transaminase and total bilirubin levels prior to the treatment in the 3 groups showed that the differences were not statistically significant (P>0.05). By contrast, after the treatment, the raising levels of glutamic-pyruvic transaminase and total bilirubin in group A were significantly lower than that in groups B and C, and the differences were statistically significant (P<0.05) (Table II).

Table II.

Comparisons among liver function damage indices.

Groups	Glutamic-pyruvic transaminase level before treatments, U/l	Raising levelsa	Total bilirubin before treatments, µmol/l	Raising levelsa
A	78.5±13.6	13.6±4.2	27.9±5.3	6.3±1.2
B	75.6±14.2	18.2±4.7	25.5±4.2	10.2±2.5
C	76.7±13.5	17.5±4.3	23.4±4.6	8.9±2.4
F-value	0.632	6.325	0.759	6.856
P-value	0.421	0.039	0.532	0.027

^aBefore treatment - after treatment.

Comparisons of survival rates

Eight patients succumbed in group A, of whom 2 had tumor recurrence in situ, 1 patient succumbed to tumor rupture hemorrhage, 3 succumbed to tumor emboli blocking the hepatic artery or portal vein hemorrhage, 3 patients succumbed to liver failure, and 1 patient had extrahepatic tumor metastasis. Mortalities occured 2 weeks to 6 months after the treatment (average, 4.2 months) and the survival rate was 77.1%. In group B, 17 patients succumbed of whom 5 patients had tumor recurrence in situ, 3 patients succumbed to tumor rupture hemorrhage, 7 patients to tumor emboli blocking the hepatic artery or portal vein hemorrhage, 5 due to liver failure, and 2 patients succumbed to extrahepatic tumor metastasis. In group B, mortalities occured 1 week to 5.5 months after treatment (average, 3.5 months), and the survival rate was 48.5%. In group C, 15 mortalities occured of whom 6 patients succumbed to tumor recurrence in situ, 4 to tumor rupture hemorrhage, 6 to tumor emboli blocking the hepatic artery or portal vein hemorrhage, 3 to liver failure, and 2 patients succumbed to extrahepatic tumor metastasis. Patients in group C succumbed to the disease 1.5 weeks to 5.6 months following treatment (average, 3.7 months), and the survival rate was 53.1%. The survival rate in group A increased significantly, and the differences were statistically significant (χ²=6.739, P=0.034).

Discussion

Ultrasound guidance technology has the advantages of real-time monitoring, accurate guidance, negligible trauma, safety and effectiveness, easy operation and repeatability (6). These advantages have led this technology to be considered as one of the three major types of treatment for liver cancer together with surgery and regional vascular intervention (7). Ultrasound guidance technology aims to effectively treat tumors or cytoreduction, reducing symptoms, improving life quality and extending survival time.

Ultrasound-guided local interstitial chemical ablation consists of injecting substances into tumors to induce necrosis. Frequently used injections include anhydrous alcohol, acetic acid, hot saline water or hot distilled water, radionuclide, biological agents and cod liver oil acid sodium anhydrous alcohol solution (8). Sugiura et al (9) clinically applied PEI in treating liver cancer for the first time, and now PEI is the most widely used method for chemical ablation. However, due to the disadvantages of non-uniform diffusion and uncontrollability of injected alcohol observed in numerous treatments of larger tumors, PEI is mainly applied in the treatment of small hepatocellular carcinoma. However, Livraghi et al (10) reported that PEI could be applied in ≥5 cm liver tumors. They showed that for the 1,066 patients participating in their study, the 3-, 5- and 7-year survival rates were 72.3, 43.2 and 27.0%, respectively. The ultrasound-guided local interstitial thermal ablation method consists of conducting energy into the tumor to inactivate tumor cells in situ. Thermal ablation includes radiofrequency, microwave, laser, refrigeration and focused ultrasound. Rossi et al (11) were the first group who reported treating small hepatocellular carcinoma using ultrasound-guided RFA, with comparable results compared to PEI. RFA can also be used as a supplementary method for the treatment of large liver tumors. RFA is also suitable for those patients that cannot tolerate surgery or those unwilling to undergo surgery. The results obtained from prior studies showed that in cancer tissues, HSP-70 expression level, AFP expression level, clinical staging, liver function classifications and the inactivated degree of tumors in liver cancer tissues, were are all closely associated with RFA treatment effects in large liver tumors (12). RFA was certified by the Food and Drug Association in early 1996 and currently is cosidered the most widely applied ablation method (13). There are some limitations associated with RFA such as high costs, limited popularity and technological difficulties.

The application of PEI in combination with RFA for the treatment of large liver cancer and liver cancer of particular areas has become a hot topic of research. This method is designed to reduce the tumor size of through dehydration and solidification using anhydrous alcohol, and thus increase the success rate of RFA ablation and reduce the frequency of ablation (14). Multi-polar RFA treatment devices (RITA Medical System; Rita Medical, Mountain View, CA, USA; Radio-Therapeutics, Sunnyvale, CA, USA) have 3–5 electrodes that are similar to ‘eagle claw’ or ‘umbrella’. The cold circulation in radiofrequency electrode is designed to prevent the ebullition and the formation of cavities of tissues around the pinpoint of the electrodes because of the heat (15). There are no absolute conclusions regarding whether PRI and RFA should be carried out seperately or simultaneously, and there are few studies on the quantitative comparison of the volume of alcohol usage and radiofrequency power. Through large numbers of clinical practices, it was identified that although the basis of liver cancer in middle and advanced stages is poor, survival time cannot be improved via conservative treatments (16). The clinical effects of simple PRI and RFA treatments are not substantial, however, the present study concluded that adimistering PEI treatment 1–2 weeks prior to RFA treatment can significantly improve the patients' condition by intensification of the volume of tumor ablation necrosis and reduce tumor volume following ablation. This method can also improve complete the ablation rate, reduce the raising levels of glutamic-pyruvic transaminase and total bilirubin and improve the survival rate. The volume of alcohol usage and radiofrequency power was not increased in this method. Possible reasons for this include: i) The stress damage of anhydrous alcohol to organic bodies is higher than that of RFA, and PEI was used for the first time (17); ii) usually there is the existence of ‘pseudocapsule’ in primary liver cancer, and PEI being used for the first time, which influences the dispersion effects of anhydrous alcohol (18); iii) the working mechanism of RFA is to use ion in tissues to create vibrations of the same frequency around electrodes, which turns it into heat energy to produce coagulative necrosis. The pretreatment of anhydrous alcohol can make the frequency of tumor tissues more concentrated, which shortens the duration of RFA (19); and iv) the simultaneous implementations of PEI and RFA treatments cannot produce a superimposed effect, which in turn creates the phenomenon of offset (20).

In conclusion, for patients with liver cancer in middle and advanced stages, the treatment method using PEI followed by RFA is more beneficial in terms of improving tumor ablation rate, alleviating liver damage and increasing survival rates.